Short answer
Allogene Therapeutics, Inc. (ALLO) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $800,000 with net income of −$43M.
Q1 2026 key financials · XBRL
- Revenue
- $800,000
- Net income
- −$43M
- +28.7% YoY
- Operating margin
- -5761.5%
- EPS (diluted)
- −$0.18
- +35.7% YoY
Source: XBRL data from the Allogene Therapeutics, Inc. (ALLO) Q1 2026 10-Q on SEC EDGAR. USD.
Allogene Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue not disclosed in provided MD&A
- Net loss $42.6M for quarter; accumulated deficit $2.1B
- Cash and investments $266.9M at March 31, 2026; April offering added $187.9M net proceeds
- Cash runway into Q1 2029; continued net losses and higher R&D and G&A expenses expected
Risk Factors
- April 2026 Public Offering triggered share-issuance constraints pending stockholder approval to increase authorized common shares
- Net loss $42.6 million in Q1 2026 and accumulated deficit $2.1 billion, sustaining substantial financing needs
- ALPHA3 interim analysis covered only 24 randomized patients, limiting confidence that results predict primary-endpoint success
- FDA may require cema-cel approval with Foresight Diagnostics’ Clarity MRD companion diagnostic
- California headquarters and manufacturing facility face earthquake, fire, and flood disruption exposure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Allogene Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.